Wird geladen...
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
BACKGROUND & AIMS: There are few real-world data on the safety of vedolizumab for treatment of Crohn’s disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. METHODS: We...
Gespeichert in:
| Veröffentlicht in: | Clin Gastroenterol Hepatol |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594363/ https://ncbi.nlm.nih.gov/pubmed/30268561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.09.035 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|